Delpharm completed the acquisition of a manufacturing plant from Sandoz Canada.

Delpharm, a developer and manufacturer of medicines for pharmaceutical companies, completed the acquisition of a manufacturing plant in Boucherville, Quebec, from Sandoz Canada, a supplier of generic pharmaceuticals and biosimilars. Financial terms were not disclosed. “We’re pleased to be partnering with a reliable CDMO like Delpharm. As part of this acquisition, we’ve signed a long-term agreement for Delpharm to provide Sandoz Canada with continuous supply of medicines manufactured in Boucherville, as well as an agreement maintaining jobs. Our injectables will continue to be manufactured in Quebec by the same expert team, and Sandoz Canada will continue to support patients, hospitals, physicians and pharmacists with the same vast portfolio of biosimilar and generic medicines, including these injectables,” Michel Robidoux, Sandoz Canada President and General Manager.